



# Roche Oncology Media Briefing Agenda

Monday 21 September, 19:00 – 20:00 (during ECCO ESMO congress)  
Radisson Blu Hotel, Berlin, Germany

18:30	Registration and refreshments
19:00	<p><b>Overview: How Roche's targeted treatments will benefit increasing numbers of patients</b> Varun Nanda, Global Product Strategy Head, Oncology, Roche</p> <p><b>Avastin in mCRC (BOXER), Rachel Wong, Royal Marsden Hospital, London, UK</b></p> <p>Avastin phase II trial: Avastin + Xeloda and oxaliplatin as neoadjuvant treatment for patients with liver-only metastases from CRC unsuitable for upfront resection (Abstract 6076) <i>Data embargoed until Wed 23 Sept, 14:00 CET</i></p> <p><b>Xeloda in adjuvant CC (968), Daniel Haller, University of Pennsylvania, Philadelphia, USA</b></p> <p>Xeloda phase III trial: XELOX versus 5-FU/LV as adjuvant therapy for patients with stage III CC who have undergone surgery (Abstract 5LBA) <i>Data embargoed until Wed 23 Sept, 14:00 CET</i></p> <p><b>Herceptin in gastric cancer (ToGA), Eric Van Cutsem, University of Leuven, Belgium</b></p> <p>Herceptin phase III trial: use of Herceptin in patients with inoperable locally advanced, recurrent and/or metastatic HER2-positive gastric cancer (Abstract 7BA) <i>Data embargoed until Thurs 24 Sept, 13:10 CET</i></p> <p><b>Avastin in melanoma (BEAM), Steven O'Day, The Angeles Clinic and Research Institute, California, USA</b></p> <p>Avastin phase II trial: Avastin added to carboplatin and paclitaxel chemo in patients with previously untreated metastatic melanoma (Abstract 23LBA) <i>Data embargoed until Wed 23 Sept 2009, 11:15 CET</i></p> <p><b>Avastin in GBM (BRAIN), James Vredenburgh, Duke University Medical Center, Durham, USA</b></p> <p>Avastin phase II trial: assessing corticosteroid use and neurocognitive function in patients with GBM at first or second relapse treated with Avastin (Abstract 8707) <i>Data embargoed until Tues 22 Sept, 10:45 CET</i></p> <p>Conclusion and close, Varun Nanda</p>
20:00 - 20:30	Meet the experts
Opportunity for individual one to one interviews throughout the congress	